Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zhejiang Jingxin Makes $10 Million Investment in Mapi Pharma of Israel

publication date: Nov 6, 2018

Zhejiang Jingxin Pharma invested $10 million in Mapi Pharma of Israel, its second $10 million investment in Mapi. Jingxin already has China rights to an unspecified Mapi product. As part of the new agreement, Mapi will develop another product exclusively for Jingxin. It will also provide Jingxin with support for registration, manufacturing and marketing of the product in China. Earlier this year, Mapi said it was developing two new products: one for schizophrenia and the other for pain, though these are not necessarily intended for Jingxin. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
ChinaBio Partnering Forum 2019
Shanghai , China
May 8-9, 2019
 
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events